MXPA06013387A - Nuevos derivados de piridazinona como inhibidores de cdk2. - Google Patents

Nuevos derivados de piridazinona como inhibidores de cdk2.

Info

Publication number
MXPA06013387A
MXPA06013387A MXPA06013387A MXPA06013387A MXPA06013387A MX PA06013387 A MXPA06013387 A MX PA06013387A MX PA06013387 A MXPA06013387 A MX PA06013387A MX PA06013387 A MXPA06013387 A MX PA06013387A MX PA06013387 A MXPA06013387 A MX PA06013387A
Authority
MX
Mexico
Prior art keywords
inhibitors
cdk2
pyridazinone derivatives
compounds
kinase
Prior art date
Application number
MXPA06013387A
Other languages
English (en)
Inventor
Swen Hoelder
Karl Schoenafinger
Hans Matter
Gunter Muller
Cecile Combeau
Christine Delaisi
Anke Steinmetz
Ingrid Sassoon
David William Will
Martin Bossart
Didier Bernard
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MXPA06013387A publication Critical patent/MXPA06013387A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a compuesto segun la formula general (I), dandose las definiciones de los sustituyentes X, R1 y R2 dados abajo en el texto, asi como a sus sales fisiologicamente aceptables, a metodos para producir estos compuestos, y a su uso como productos farmaceuticos. Estos compuestos son inhibidores de cinasa, en particular inhibidores de la cinasa CDK2 (cinasa 2 dependiente de ciclina).
MXPA06013387A 2004-05-18 2005-05-17 Nuevos derivados de piridazinona como inhibidores de cdk2. MXPA06013387A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04011735A EP1598348A1 (en) 2004-05-18 2004-05-18 Novel pyridazinone derivatives as inhibitors of CDK2
PCT/EP2005/006046 WO2005111019A1 (en) 2004-05-18 2005-05-17 Novel pyridazinone derivatives as inhibitors of cdk2

Publications (1)

Publication Number Publication Date
MXPA06013387A true MXPA06013387A (es) 2007-06-22

Family

ID=34925033

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06013387A MXPA06013387A (es) 2004-05-18 2005-05-17 Nuevos derivados de piridazinona como inhibidores de cdk2.

Country Status (14)

Country Link
US (2) US7507734B2 (es)
EP (2) EP1598348A1 (es)
JP (1) JP4842261B2 (es)
KR (1) KR20070014180A (es)
CN (1) CN1972930A (es)
AR (1) AR049100A1 (es)
AU (1) AU2005243493A1 (es)
BR (1) BRPI0510151A (es)
CA (1) CA2567154A1 (es)
IL (1) IL178968A0 (es)
MX (1) MXPA06013387A (es)
TW (1) TW200607805A (es)
UY (1) UY28903A1 (es)
WO (1) WO2005111019A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212146B2 (en) 2008-03-18 2015-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted pyridazinones for the treatment of tumors
CN101537006B (zh) 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
US20100267706A1 (en) * 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
ES2469990B1 (es) * 2012-12-19 2015-01-26 Universidade De Vigo Compuestos de estructura híbrida piridazinona ditiocarbamato con actividad antineoplásica
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
CN107334767B (zh) * 2017-06-08 2019-03-05 中国医学科学院医药生物技术研究所 一种哒嗪酮类化合物在肿瘤治疗中的应用
CN109568256A (zh) * 2018-12-21 2019-04-05 江西润泽药业有限公司 一种cdk抑制剂注射液及其制备方法
CN111533735A (zh) * 2020-05-08 2020-08-14 张建蒙 氧代二氢哒嗪噻唑类衍生物及其在抗肿瘤药物中的应用
CN111393374A (zh) * 2020-05-08 2020-07-10 张建蒙 氧代二氢哒嗪类衍生物及其在抗肿瘤药物中的应用
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN114042069A (zh) * 2021-10-22 2022-02-15 陕西国际商贸学院 一种5-取代哒嗪-4-胺衍生物、制备方法和用途
CN115650968B (zh) * 2022-12-27 2023-03-21 英矽智能科技(上海)有限公司 作为cdk选择性抑制剂的新型哒嗪酮化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU190412B (en) 1981-09-17 1986-09-29 Warner-Lambert Co,Us Process for producing substituted 4,5-dihiydro-6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones and 6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones
US4353905A (en) 1981-09-17 1982-10-12 Warner-Lambert Company Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones
US4734415A (en) 1982-08-13 1988-03-29 Warner-Lambert Company Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones
DE4324580A1 (de) * 1993-07-22 1995-01-26 Thomae Gmbh Dr K Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH09216883A (ja) * 1996-02-09 1997-08-19 Fujisawa Pharmaceut Co Ltd ピラゾロピリジン化合物および該化合物を含有する医薬
DE60017179T2 (de) * 1999-10-19 2006-01-05 Merck & Co., Inc. Tyrosin kinaseinhibitoren
HUP0302173A2 (hu) * 2000-09-15 2003-09-29 Vertex Pharmaceuticals Incorporated Protein kináz inhibitorokként alkalmazható pirazolvegyületek
JP2005022972A (ja) * 2001-05-16 2005-01-27 Teikoku Hormone Mfg Co Ltd ４−（４−ピリダジニル）ピラゾール誘導体
DE10133399A1 (de) 2001-07-13 2003-01-23 Cognis Deutschland Gmbh Zusammensetzung auf Wachsbasis
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
BR0306988A (pt) * 2002-01-18 2004-11-23 Pharmacia Corp Piridazinonas substituìdas como inibidores de p38
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
DE102004010194A1 (de) 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors

Also Published As

Publication number Publication date
US20090130209A1 (en) 2009-05-21
KR20070014180A (ko) 2007-01-31
US7507734B2 (en) 2009-03-24
BRPI0510151A (pt) 2007-10-02
CA2567154A1 (en) 2005-11-24
CN1972930A (zh) 2007-05-30
US20070259870A1 (en) 2007-11-08
EP1751141A1 (en) 2007-02-14
UY28903A1 (es) 2005-12-30
WO2005111019A1 (en) 2005-11-24
AU2005243493A1 (en) 2005-11-24
EP1598348A1 (en) 2005-11-23
JP4842261B2 (ja) 2011-12-21
AR049100A1 (es) 2006-06-28
US7968546B2 (en) 2011-06-28
TW200607805A (en) 2006-03-01
IL178968A0 (en) 2007-03-08
JP2008509884A (ja) 2008-04-03

Similar Documents

Publication Publication Date Title
MXPA06013387A (es) Nuevos derivados de piridazinona como inhibidores de cdk2.
TW200607804A (en) Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
MX2009010595A (es) Derivados de pirrolopirimidina.
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
MX2009007302A (es) Derivados de purina.
TW200618800A (en) Heterocyclic compounds
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
MY153727A (en) Pyridazinone derivatives
TW200630374A (en) Thiazolyldihydroindazoles
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
RS95404A (en) Thiazolidinones and the use thereof as polo-like kinase inhibitors
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
TW200722424A (en) Substituted piperidines
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
UA99485C2 (ru) Хиназолиндионовые производные, их получение и их применение в терапии
TW200730511A (en) Chroman compounds
TW200740795A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
TW200730510A (en) Chroman compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal